GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Omni Bio Pharmaceutical Inc (GREY:OMBP) » Definitions » Shares Outstanding (EOP)

Omni Bio Pharmaceutical (Omni Bio Pharmaceutical) Shares Outstanding (EOP) : 40.21 Mil (As of Dec. 2014)


View and export this data going back to 2007. Start your Free Trial

What is Omni Bio Pharmaceutical Shares Outstanding (EOP)?

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Omni Bio Pharmaceutical's shares outstanding for the quarter that ended in Dec. 2014 was 40.21 Mil.

Omni Bio Pharmaceutical's quarterly shares outstanding increased from Sep. 2014 (39.01 Mil) to Dec. 2014 (40.21 Mil). It means Omni Bio Pharmaceutical issued new shares from Sep. 2014 to Dec. 2014 .

Omni Bio Pharmaceutical's annual shares outstanding increased from Mar. 2013 (32.02 Mil) to Mar. 2014 (38.66 Mil). It means Omni Bio Pharmaceutical issued new shares from Mar. 2013 to Mar. 2014 .


Omni Bio Pharmaceutical Shares Outstanding (EOP) Historical Data

The historical data trend for Omni Bio Pharmaceutical's Shares Outstanding (EOP) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Omni Bio Pharmaceutical Shares Outstanding (EOP) Chart

Omni Bio Pharmaceutical Annual Data
Trend Dec06 Dec07 Dec08 Mar09 Mar10 Mar11 Mar12 Mar13 Mar14
Shares Outstanding (EOP)
Get a 7-Day Free Trial Premium Member Only 27.99 28.98 32.02 32.02 38.66

Omni Bio Pharmaceutical Quarterly Data
Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14
Shares Outstanding (EOP) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 38.66 38.66 38.86 39.01 40.21

Competitive Comparison of Omni Bio Pharmaceutical's Shares Outstanding (EOP)

For the Biotechnology subindustry, Omni Bio Pharmaceutical's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Omni Bio Pharmaceutical's Shares Outstanding (EOP) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Omni Bio Pharmaceutical's Shares Outstanding (EOP) distribution charts can be found below:

* The bar in red indicates where Omni Bio Pharmaceutical's Shares Outstanding (EOP) falls into.



Omni Bio Pharmaceutical Shares Outstanding (EOP) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that end of period. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.


Omni Bio Pharmaceutical  (GREY:OMBP) Shares Outstanding (EOP) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Omni Bio Pharmaceutical Shares Outstanding (EOP) Related Terms

Thank you for viewing the detailed overview of Omni Bio Pharmaceutical's Shares Outstanding (EOP) provided by GuruFocus.com. Please click on the following links to see related term pages.


Omni Bio Pharmaceutical (Omni Bio Pharmaceutical) Business Description

Traded in Other Exchanges
N/A
Address
5350 South Roslyn, Suite 430, Greenwood Village, CO, USA, 80111
Omni Bio Pharmaceutical Inc is a US-based biopharmaceutical company, which is engaged in the exploration of new methods of use of alpha-1 antitrypsin (AAT). It offers AAT, a naturally occurring protein that is essential for normal liver and lung function and has been purified from human blood to treat patients suffering from emphysema due to AAT-deficiency. Further, it focuses on the research and development efforts of advancing its first recombinant molecule, AAT and an Fc component of immunoglobulin (AAT-Fc 2) into clinical trials. Geographically these activities are functioned through the region of US.

Omni Bio Pharmaceutical (Omni Bio Pharmaceutical) Headlines

No Headlines